Pascale Diesel recently wrote an article that explores the high cost of gene and cell therapies and the need for companies to provide higher levels of support for healthcare providers and patients through access, reimbursement, and financing.
The new generation of emerging gene and cell therapy companies are advancing many promising treatments for major areas of unmet need in healthcare and have the potential to transform the biopharmaceutical industry in the future. The sector as a whole is trending toward more M&A deals, meaning smaller life sciences companies need to consider several factors before implementing a commercialization strategy.Their success will be based on their ability to refine their go-to-market models, geographic strategies, and maximize efficiency.
France: A step towards more regulated drug prices
2022 was an expensive year for public spending in France, that led to a €18.9 billion debt for the social security system, of which almost 90% was driven by...